Literature DB >> 21264875

Prevalence of norovirus GII-4 antibodies in Finnish children.

K Nurminen1, V Blazevic, L Huhti, S Räsänen, T Koho, V P Hytönen, T Vesikari.   

Abstract

Noroviruses (NoVs) are the second most common cause of viral gastroenteritis after rotavirus in children. NoV genotype GII-4 has emerged as the major type not only in outbreaks of NoV gastroenteritis but also endemic gastroenteritis among infants and young children worldwide. Using baculovirus-insect cell system virus-like particles (VLPs) of NoV genotype GII-4 and an uncommon genotype GII-12 were produced. These VLPs were used in enzyme-linked immunosorbent assays (ELISA) for detection of NoV-specific immunoglobulin G (IgG) and IgA antibodies in 492 serum specimens from Finnish children 0-14 years of age collected between 2006 and 2008. NoV IgG antibody prevalence was 47.3% in the age group 7-23 months and increased up to 91.2% after the age of 5 years. Avidity of NoV IgG antibodies was low in the primary infections while high avidity antibodies were detected in the recurrent infections of the older children. In GII-4 infections, the homologous antibody response to GII-4 VLPs was stronger than to GII-12 VLPs but cross-reactivity between GII-4 and GII-12 was observed. Binding of GII-4 VLPs to a putative carbohydrate antigen receptor H-type 3 could be blocked by sera from children not infected with NoV during a waterborne outbreak of acute gastroenteritis. Therefore, protection against NoV infection correlated with strong blocking activity.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21264875     DOI: 10.1002/jmv.21990

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  29 in total

1.  Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity.

Authors:  Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Veronica Costantini; Martina Beltramello; Davide Corti; Jesica Swanstrom; Antonio Lanzavecchia; Jan Vinjé; Ralph S Baric
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

2.  Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Hanni Uusi-Kerttula; Timo Vesikari; Vesna Blazevic
Journal:  Clin Vaccine Immunol       Date:  2015-04-22

3.  Seroepidemiology of norovirus-associated travelers' diarrhea.

Authors:  Nadim J Ajami; Owen V Kavanagh; Sasirekha Ramani; Sue E Crawford; Robert L Atmar; Zhi-Dong Jiang; Pablo C Okhuysen; Mary K Estes; Herbert L DuPont
Journal:  J Travel Med       Date:  2014 Jan-Feb       Impact factor: 8.490

4.  A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.

Authors:  Kirsi Tamminen; Leena Huhti; Tiia Koho; Suvi Lappalainen; Vesa P Hytönen; Timo Vesikari; Vesna Blazevic
Journal:  Immunology       Date:  2012-01       Impact factor: 7.397

5.  Exposure to human and bovine noroviruses in a birth cohort in southern India from 2002 to 2006.

Authors:  Vipin Kumar Menon; Santosh George; Aruna A Shanti; Anuradha Saravanabavan; Prasanna Samuel; Sasirekha Ramani; Mary K Estes; Gagandeep Kang
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

Review 6.  Norovirus immunology: Of mice and mechanisms.

Authors:  Kira L Newman; Juan S Leon
Journal:  Eur J Immunol       Date:  2015-08-25       Impact factor: 5.532

Review 7.  Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.

Authors:  Negar Aliabadi; Ben A Lopman; Umesh D Parashar; Aron J Hall
Journal:  Expert Rev Vaccines       Date:  2015-07-29       Impact factor: 5.217

8.  Genetic susceptibility to norovirus GII.3 and GII.4 infections in Chinese pediatric diarrheal disease.

Authors:  Pengbo Liu; Xiaoqin Wang; Joong-Chul Lee; Peter Teunis; Senke Hu; Helen Tang Paradise; Christine Moe
Journal:  Pediatr Infect Dis J       Date:  2014-11       Impact factor: 2.129

9.  Evaluation of anti-norovirus IgY from egg yolk of chickens immunized with norovirus P particles.

Authors:  Ying-Chun Dai; Yun-Yun Wang; Xu-Fu Zhang; Ming Tan; Ming Xia; Xian-Bo Wu; Xi Jiang; Jun Nie
Journal:  J Virol Methods       Date:  2012-08-04       Impact factor: 2.014

10.  A dual chicken IgY against rotavirus and norovirus.

Authors:  Ying-Chun Dai; Xu-Fu Zhang; Ming Tan; Pengwei Huang; Wen Lei; Hao Fang; Weiming Zhong; Xi Jiang
Journal:  Antiviral Res       Date:  2012-12-22       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.